Caitong International Asset Management Co., LTD Cardiff Oncology, Inc. Transaction History
Caitong International Asset Management Co., LTD
- $102 Billion
- Q4 2024
A detailed history of Caitong International Asset Management Co., LTD transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Caitong International Asset Management Co., LTD holds 1,346 shares of CRDF stock, worth $5,774. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,346
Previous 1,346
-0.0%
Holding current value
$5,774
Previous $5.84 Million
-0.0%
% of portfolio
0.01%
Previous 0.01%
Shares
1 transactions
Others Institutions Holding CRDF
# of Institutions
114Shares Held
16.2MCall Options Held
694KPut Options Held
140K-
Commodore Capital LP New York, NY5.38MShares$23.1 Million2.34% of portfolio
-
Black Rock Inc. New York, NY2.63MShares$11.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.28MShares$9.8 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA1.54MShares$6.6 Million0.18% of portfolio
-
Acorn Capital Advisors, LLC New York, NY1.44MShares$6.19 Million3.38% of portfolio
About Cardiff Oncology, Inc.
- Ticker CRDF
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,334,900
- Market Cap $186M
- Description
- Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...